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Identity 
Other names: ANX1, LPC1 
HGNC (Hugo): ANXA1  
Location: 9q21.13 
Local order: According to NCBI Map Viewer, genes 
flanking ANXA1 in centromere to telomere direction 
on 9q21 are: LOC100289351, RPS20P24, TMC1, 
RPS27AP15, ALDH1A1, LOC100133307, 
LOC100132782, ANXA1, LOC138971, 
LOC100130911, RORB, TRPM6, RNY4P1. 
DNA/RNA 
Description 
The exon-intron organization of ANXA1 genes in 
vertebrates have been described and are highly 
conserved, each gene consisting of 13 exons of which 
the first and last are uncoding 5' and 3'  
sequences, with the translation initiator codon (AUG) 
found near the beginning of the second exon (Kovacic 
et al., 1991). 
Transcription 
Transcription produces 9 different mRNAs to this gene. 
The ANXA1 gene is expressed in the tissues: bone, 
bone marrow, brain, cartilage, cerebellum, cerebrum, 
cervix, colon, ear, embryonic tissue, endocrine, 
esophagus, eye, fetus, gastrointestinal tract, heart, 
kidney, liver, lung, lymph node, lymphoreticular, 
mammary gland, muscle, nervous, ovary, pancreas, 
pancreatic islet, parathyroid, peripheral nervous system, 
pituitary gland, placenta, pooled tissue, prostate, 
salivary gland, skin, soft tissue, spleen, stem cell, 
stomach, synovium, t-cell, testis, thymus, thyroid, 
uncharacterized tissue, uterus, vascular. 
Pseudogene 
No known pseudogenes. 
 
ANXA1 gene. The ANXA1 gene contains 13 exons, of which the first and last are uncoding 5' and 3' sequences (red regions), with the 
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Belongs to the annexin family. Contains 4 annexin 
repeats. 
Description 
The ANXA1 gene encodes a 38.71 kDa protein. 
Similarly to other annexins, annexin A1 is 
characterized by a C-terminal homologous domain with
4 to 8 repeats of 70-75 aminoacids, responsible for 
calcium and phospholipid binding properties. The 
variable N-terminal region is unique in length and 
sequence and includes potential sites of 
phosphorylation, glycosylation and peptidase action 
(Gerke and Moss, 2002). 
Expression 
The human ANXA1 gene promoter contains consensus 
sequences for: glucocorticoids, AP-1 and NFIL-6. 
However the regulation from glucocorticoid (GC) 
appear to be dependent upon an activation involving 
NFIL-6 or AP1 (Solito et al., 1998a; Solito et al., 
1998b). The GC mediated regulations confirm the 
original studies which proposed ANXA1 as mediator of 
the glucocorticoid action (Flower, 1988). In mouse, in 
contrast, GC regulation is mediated through two 
consensus sequences present in the upstream region of 
TATA box (Horlick et al., 1991). However the data of 
Antonicelli et al. 2001 regarding sequences of the 
mouse Anxa1 promoter brought evidence of the 
involvement of the CREB transcription factor (the 
cyclic AMP-responding element-binding protein) in the 
activation of this gene by cyclic AMP and 
glucocorticoids. 
Localisation 
ANXA1 is preferentially localized in the cytoplasm and 
associated with the plasma membrane or cytoskeleton, 
but it has also been localized outside the plasma 
membrane. 
Function 
The function of the annexin A1 is far to be clear, it has 
been involved in signal transduction (Alldridge et al., 
1999; de Coupade et al., 2000), vesicle transport 
(Diakonova et al., 1997), cell transformation (Violette 
et al., 1990; Solito et al.,  
1998a), inflammation (Perretti and Gavins, 2003), cell
matrix interaction and apoptosis (Raynal and Pollard, 
1994; Solito et al., 2001; Solito et al., 2003). 
Homology 
The comparison of conserved and variable residues 
between human annexin 1 protein and annexin protein 
from different vertebrates shows amino acid identities 
of 100% (Pan troglodytes), 91% (Canis familiars), 87% 
(Mus musculus), 89% (Rattus norvegicus) and 77% 
(Gallus gallus) (Rodrigues-Lisoni et al., 2006). 
Mutations 
Note 
Reduced expression of ANXA1 could be explain by 
some mechanisms include gene deletions and 
mutations, hyper-methylation of the promoter with 
subsequent loss of transcription, and alterations in the 
post-translation processing (e.g. phosphorylation) f 
the protein involved in annexins regulation (de 
Coupade et al., 2000; Rodrigues-Lisoni et al., 2006; 
Alves et al., 2008).  
Lindgren et al. (2001) studied subjects with type 2 
diabetes and find a G instead of T at nucleotide position 
362 from the transcription start site (exon 5) of 




In breast cancer, ANXA1 is believed to function as a 
tumor suppressor. In study with a tissue microarray 
using 82 pairs of primary breast cancers and lymph 
node metastases from archival materials the results 
revealed that ANXA1 expression was lost in 79% of 
breast carcinomas, and there was no difference in 
ANXA1 expression between primary breast carcinoma 
and lymph node metastasis (Cao et al., 2008). 
Prognosis 
The suppressed ANXA1 expression in breast tissue is 
correlated with breast cancer development, progression 
and metastasis (Shen et al., 2006; Wang et al., 2010). 
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Oral squamous cell carcinoma (OSCC) 
Disease 
ANXA1 expression could be used as a suitable 
biomarker for patients with oral cavity cancer and its 
adoption for complementary non-invasive diagnosis of 
oral squamous cell carcinoma is suggested. Beyond the 
anti-inflammatory function, annexin A1 may also play 
a tumor suppressor role in peripheral blood cells (Faria 
et al., 2010). 
Prognosis 
The nuclear localization of ANXA1 protein is a 
frequent event and could be used as a prognostic factor 
in OSCC (Lin et al., 2008). 
Laryngeal squamous cell carcinoma 
Disease 
In surgical tissue specimens from 20 patients with 
laryngeal squamous cell carcinoma, ultrastructural 
immunocytochemistry analysis showed in vivo down-
regulation of ANXA1 expression in the tumor and 
increased in mast cells and laryngeal squamous 
carcinoma cell line treated with ANXA1 peptide. 
Combined in vivo and in vitro analysis demonstrated 
that ANXA1 plays a regulatory role in laryngeal caner 
cell growth (Silistino-Souza et al., 2007). 
Prognosis 
ANXA1 dysregulation was observed early in laryngeal 
carcinogenesis, in intra-epithelial neoplasms (Alves et 
al., 2008). 
Lung squamous cell carcinoma 
Disease 
The ANXA1 expression was identified by shot-gun 
proteomics strategy in lung squamous cell carcinoma. 
Prognosis 
The ANXA1 might play an important role in lung 
squamous cell carcinoma genesis, progression, 
recurrence, and metastasis and might be used as 
markers of this carcinoma (Nan et al., 2009). 
Prostate cancer 
Disease 
The reduction of ANXA1 expression, commonly 
associated with prostate cancer, could be due to 
elevated activity of histone deacetylases (D'Acunto et 
al., 2010) and interleukin 6 expression (Inokuchi et al., 
2009). 
Prognosis 
The ANXA1 expression is a contributing factor to the 
proapoptotic effects in prostate cancer (D'Acunto et al., 
2010) and enhancing tumor aggressiveness via the 
upregulation of interleukin 6 expression and activity 






Immunocytochemical detection of ANXA1 represents a  
simple, inexpensive, highly sensitive and specific 
(100%) assay for diagnosis of hairy cell leukaemia. 
This assay will be especially useful in distinguishing 
hairy cell leukaemia from splenic lymphoma with 
villous lymphocytes and variant hairy cell leukaemia, 
both of which usually respond poorly to treatments that
are effective in hairy cell leukaemia (Falini et al., 
2004). 
Prognosis 
The downregulated ANXA1 expression contributes 
considerably to the drug resistance in leukemia cell lin  
(Zhu et al., 2009). 
Cervical cancer 
Disease 
A close association was observed between ANXA1 
expression and tumour cell differentiation in invasi e 
squamous cell carcinoma. 
Prognosis 
ANXA1 may be an effective candidate for detecting 
cervical intraephitelial neoplasia lesions and for 
evaluating tumour cell differentiation in squamous cell 
carcinoma of the cervix (Wang et al., 2008). 
Gastric cancer 
Disease 
Loss of ANXA1 expression was significantly 
associated with advanced T stage, lymph node 
metastasis, advanced disease stage, and poor 
histological differentiation. 
Prognosis 
ANXA1 expression decreased significantly as gastric 
cancer progressed and metastasized, suggesting the 
importance of ANXA1 as a negative biomarker for 
gastric cancer development and progression (Yu et al., 
2008). 
Urinary bladder urothelial carcinoma 
Disease 
Comparative proteomics and immunohisto-chemistry 
demonstrated that ANXA1 is up-regulated in high 
grade urinary bladder urothelial carcinoma as compared 
to non-high grade carcinomas. 
Prognosis 
ANXA1 might be related to tumour progression. The 
ANXA1 overexpression and histological grade 
predicted disease-specific survival and metastasis-free 
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Systemic lupus erythematosus 
Disease 
Auto-antibodies against annexin A1 have been  
detected in patients with auto-immune diseases suchas 
systemic lupus erythematosus (Hirata et al., 1981; 
Goulding et al., 1989). 
Rheumatoid arthritis 
Disease 
ANXA1 has been recently shown to play a key role in 
T-cell activation and to be highly expressed in T cells 
from rheumatoid arthritis patients. Treatment of 
rheumatoid arthritis patients with steroid decreased 
ANXA1 expression in T cells. 
Prognosis 
Steroids regulate the adaptive immune response and 
suggest that ANXA1 may represent a target for the 




Corticosteroids are widely used to treat patients with 
inflammatory bowel disease although the response is 
variable. Corticosteroids mediate some of their actions 
through ANXA1, and the induction of autoantibodies to 
ANXA1 has been proposed as a possible mechanism by 
which steroid efficacy is suboptimal in vivo (Beattie et 
al., 1995). 
Prognosis 
The high levels of IgM ANXA1 antibodies in patients 
with Crohn's disease not taking corticosteroids provides 
further evidence of disturbed immunity in 
inflammatory bowel disease (Stevens et al., 1993). 
Cystic fibrosis 
Disease 
Downregulation and degradation of ANXA1 was found 
in the bronchoalveolar lavage fluid of patients with 
cystic fibrosis indicating the susceptibility of these 
patients to lung inflammation. ANXA1 may be a key 
protein involved in cystic fibrosis pathogenesis 
especially in relation to the not well defined field of 
inflammation in cystic fibrosis (Tsao et al., 1998). 
Prognosis 
Decreased expression of annexin A1 contributes to the 
worsening of the cystic fibrosis phenotype (Bensalem 
et al., 2005). 
Parkinson's disease 
Disease 
ANXA1 expression has been linked to Parkinson's 
disease. ANXA1 immunoreactivity has been found in 
ameboid microglia within the astrocytic envelope of 
neurons adjacent to or within glial scars in the 
parkinsonian substantia nigra (Knott et al., 2000). 
Multiple sclerosis 
Disease 
ANXA1 expression has been identified in the lesions f 
multiple sclerosis plaque and correlated with the degree 
of the disease (Probst-Cousin et al., 2002). 
Prognosis 
Strategies aiming at reducing ANXA1 functions or 
expression in T cells might represent a novel 
therapeutic approach for multiple sclerosis (Paschalidis 
et al., 2009). 
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